Login / Signup

Unlocking DOE potential by selecting the most appropriate design for rAAV optimization.

Konstantina TzimouDavid Catalán-TatjerLars K NielsenJesús Lavado-García
Published in: Molecular therapy. Methods & clinical development (2024)
Producing recombinant adeno-associated virus (rAAV) for gene therapy via triple transfection is an intricate process involving many cellular interactions. Each of the different elements encoded in the three required plasmids-pHelper, pRepCap, and pGOI-plays a distinct role, affecting different cellular pathways when producing rAAVs. The required expression balance emphasizes the critical need to fine-tune the concentration of all these different elements. The use of design of experiments (DOE) to find optimal ratios is a powerful method to streamline the process. However, the choice of the DOE method and design construction is crucial to avoid misleading results. In this work, we examined and compared four distinct DOE approaches: rotatable central composite design (RCCD), Box-Behnken design (BBD), face-centered central composite design (FCCD), and mixture design (MD). We compared the abilities of the different models to predict optimal ratios and interactions among the plasmids and the transfection reagent. Our findings revealed that blocking is essential to reduce the variability caused by uncontrolled random effects and that MD coupled with FCCD outperformed all other approaches, improving volumetric productivity 109-fold. These outcomes underscore the importance of selecting a model that can effectively account for the biological context, ultimately yielding superior results in optimizing rAAV production.
Keyphrases
  • gene therapy
  • escherichia coli
  • poor prognosis
  • climate change
  • type diabetes
  • risk assessment
  • binding protein
  • metabolic syndrome
  • klebsiella pneumoniae
  • glycemic control
  • neural network